Codexis Q2 revenue up 51% to $38.4M; CEO Nicols to retire; Dilly appointed

CODEXIS, INC.

2022-Q2 EPS reported -$0.17 revenue$73,746,000

Product revenue surged 135% YoY to $34.6M, driven by Pfizer PAXLOVID enzyme sales.
Net loss narrowed to $2.6M ($0.04 per share) from $4.3M a year ago.
CEO John Nicols retiring for family reasons; Dr. Stephen Dilly to become CEO on Aug 9, 2022.
Reaffirmed FY2022 guidance: total revenue $135-141M, product revenue $112-118M incl. ~$75M from Pfizer.
Cash and equivalents $90.1M; expects to fund operations through end of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.